Insightful interview with a biotech CEO discussing the company's focus on antisense therapies and the potential of their lead asset in treating Duchenne Muscular Dystrophy |James Garner, CEO,Antisense Therapeutics Ltd 00:10:00

Share On Facebook Share On Twitter

An interview with the CEO of a biotech company shedding light on the potential of antisense therapies, particularly focusing on their lead asset's role in treating Duchenne Muscular Dystrophy, and outlining the strategic priorities and upcoming milestones for the company.

Recent Videos